Most U.S. hospitals have a broad portfolio of digital technologies already in place and other innovations in early development or deployment stages, but far fewer qualify as so-called smart hospitals.
The global medical sensors market is estimated to reach $15.01 billion by 2022, at a CAGR of 8.5% between 2016 and 2022. People are increasingly adopting home healthcare services owing to the rising costs of medical treatments in hospitals and medical care clinics. With this, the demand for various healthcare devices is expected to increase in the next few years.
For the first time ever, a mobile video game used to assess and treat a disease is headed for an FDA review.
The Prostate Health Index (phi) (Beckman Coulter) significantly changes urologists' opinions about whether men with certain results on prostate-specific antigen (PSA) screening should or should not undergo a prostate biopsy to assess for cancer, according to new observational research.
Research shows that teenagers who used a mobile health app once a day in conjunction with medical care improved concussion symptoms.
Regardless of what it’s protecting you against, few people would likely say that getting a vaccine injection is an altogether enjoyable vaccine. Fortunately, engineers at the Massachusetts Institute of Technology are coming to the rescue with a new 3D fabrication technique that could allow for multiple doses of a drug or vaccine to be delivered to a patient over an extended period of time — with just one jab needed.
The U.S. Food and Drug Administration(FDA) permitted marketing of the first mobile medical application to help treat substance use disorders (SUD). The Reset application is intended to be used with outpatient therapy to treat alcohol, cocaine, marijuana and stimulant SUDs. The application is not intended to be used to treat opioid dependence.
In support of the project in adopting Atlas Genetic's io rapid diagnostic platform into UK sexual health clinics, Innovative UK has awarded them a grant of £2 million.
Commenting on the Group’s results, Roche CEO Severin Schwan said: “In the first half of the year, both our Pharmaceuticals and Diagnostics Divisions showed strong performance, very much driven by new product launches. Particularly pleasing is the very successful launch of Ocrevus for the treatment of two forms of multiple sclerosis. Based on our half-year performance, we raised the outlook for the full-year to mid-single digit sales growth.”
Growth in prescriptions for diabetes medicines is exceeding the rise in overall prescribing, according to new figures from NHS Digital.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.